Skip to main content
TipRanks
Go Ultimate75% OFF

BioInvent International AB (BOVNF) Drug Pipeline

5 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Pembrolizumab (Keytruda®), Bi-1607, Ipilimumab (Yervoytm, 50 Mg/10 Ml Solution)Melanoma, Melanoma Metastatic, Melanoma Of Skin, Melanoma Braf V600e/K Mutated, Melanoma Recurrent, Melanoma Stage Iii Or Iv, Melanoma Negative For Braf, Melanoma Negative For Nras, Melanomas, Uveal Melanoma, Metastaticphase1AndPhase2RecruitingDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaDec 16, 2024―
Pembrolizumab, Bi-1910Non Small Cell Lung Cancer, Solid Tumors, Hepatocellular Carcinomaphase1AndPhase2RecruitingBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid TumorsDec 18, 2023―
Trastuzumab, Bi-1607Metastatic Gastric Adenocarcinoma, Her2-Positive Metastatic Breast Cancer, Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinomaphase1AndPhase2TerminatedBI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid TumorsSep 22, 2022―
Bt-001, Pembrolizumab [Keytruda®]Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Metastatic Cancer, Merkel Cell Carcinoma, Soft Tissue Sarcomaphase1AndPhase2RecruitingA Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsJan 25, 2021―
Bi-1808, Pembrolizumab (Keytruda® ) 25 Mg/Ml Solution For InjectionOvarian Cancer, Melanoma, Advanced Malignancies, T-Cell Lymphomaphase1AndPhase2RecruitingBI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)Dec 15, 2020―
Bi1206Solid Tumor, Adultphase1AndPhase2RecruitingA Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)Oct 21, 2019―
Rituximab, Acalabrutinib, Bi-1206Indolent B-Cell Non-Hodgkin Lymphomaphase1AndPhase2RecruitingA Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLMay 17, 2018―
Bi-505, High Dose Melphalan, Autologous Stem Cell TransplantationMultiple Myelomaphase1AndPhase2TerminatedA Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple MyelomaApr 18, 2016―
Bi-505Smoldering Multiple MyelomaPhase IITerminatedA Phase II Study of BI-505 in Smoldering Multiple MyelomaMar 26, 2013―
Mldl1278a, Statin, Stable DoseAtherosclerosisPhase IICompletedA Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)Dec 10, 2010―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BioInvent International AB (BOVNF) have in its pipeline
BioInvent International AB BOVNF is currently developing the following drugs: Pembrolizumab (Keytruda®), Bi-1607, Ipilimumab (Yervoytm, 50 Mg/10 Ml Solution), Pembrolizumab, Bi-1910, Trastuzumab, Bi-1607, Bt-001, Pembrolizumab [Keytruda®], Bi-1808, Pembrolizumab (Keytruda® ) 25 Mg/Ml Solution For Injection, Bi1206, Rituximab, Acalabrutinib, Bi-1206, Bi-505, High Dose Melphalan, Autologous Stem Cell Transplantation, Bi-505, Mldl1278a, Statin, Stable Dose, Tb-403. These drug candidates are in various stages of clinical development as the company works toward FDA approval.